1. As of noon trading, Northrop Grumman ( NOC) is up $0.72 (0.8%) to $91.28 on average volume. Thus far, 689,256 shares of Northrop Grumman exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $90.21-$91.39 after having opened the day at $90.22 as compared to the previous trading day's close of $90.56.

Northrop Grumman Corporation provides systems, products, and solutions in aerospace, electronics, information systems, and technical service areas to government and commercial customers worldwide. Northrop Grumman has a market cap of $20.8 billion and is part of the aerospace/defense industry. Shares are up 33.8% year to date as of the close of trading on Friday. Currently there are 2 analysts that rate Northrop Grumman a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Northrop Grumman as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Northrop Grumman Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the industrial goods sector could consider Industrial Select Sector SPDR ( XLI) while those bearish on the industrial goods sector could consider ProShares Short Dow 30 ( DOG).
null

If you liked this article you might like

These Stocks Are Changing Course

Analysts' Actions -- Citizens Financial, Expedia, First Solar, Jack in the Box and More

Stratasys Stock Drops Premarket Despite 4Q Beat

Treehouse Foods, Arconic, Kinder Morgan, Chesapeake Energy: 'Mad Money' Lightning Round

Trump's Tweet Creates Opportunity in Pharma: Cramer's 'Mad Money' Recap (Tuesday 2/7/17)